Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Background: This study aimed to analyze the cost effectiveness of camrelizumab in the second-line treatment of advanced or metastatic esophageal squamous cell carcinoma in China.Methods: On the basis of the ESCORT clinical trial, a partitioned survival model was constructed to simulate the patient’s...

Full description

Bibliographic Details
Main Authors: Hongfu Cai, Baohua Xu, Na Li, Bin Zheng, Zhiwei Zheng, Maobai Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-11-01
Series:Frontiers in Pharmacology
Subjects:
cost-effectiveness
esophageal cancer
esophageal squamous cell carcinoma
chemotherapy
camrelizumab
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.732912/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.732912/full

Similar Items